PIRS (Pieris Pharmaceuticals) Forward P/S Multiple

Corporate emblem and logo of Pieris Pharmaceuticals (PIRS)

Risks are associated with crisis management and the struggle for capital survival for Pieris Pharmaceuticals (PIRS). This chart on the GURU.Markets platform illustrates the expected revenue multiple, where the 821.20 metric determines the status of the support parameter. Stability is based on protein test outcomes, while growth potential relies on the development of the Anticalin platform and new partnerships with biotech firms.

Pieris Pharmaceuticals, Inc. - PIRS Market Cap to Future Revenue Ratio (period 07/04/2022 - 12/31/2025)

Analytical breakdowns for Pieris Pharmaceuticals

- market price and analyst price targets:
Price Chart Pieris Pharmaceuticals, Inc.|PIRS - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization Pieris Pharma|PIRS - Company Buyout Price
- issuer book value statistics:
Book Value per Share Pieris Pharmaceuticals|PIRS - Total Stockholders' Equity|Market Value to Book Value Ratio pieris.com|PIRS - Aggregate Asset Value
- company liabilities and liquidity data:
Total Debt to Capital Pieris Pharmaceuticals|PIRS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Pieris Pharmaceuticals|PIRS - Company Total Debt Obligations|Debt to Book Value Pieris Pharma|PIRS - Company Long-Term Loans and Borrowings|Company Short-Term Debt Pieris Pharmaceuticals|Quick Ratio pieris.com
- financial results and valuation multiples details:
PIRS - Final Profit|Projected Future Earnings Pieris Pharmaceuticals|PIRS - P/E Multiple|Future Price to Earnings Pieris|PIRS - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharma|PIRS - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Pieris Pharmaceuticals|PIRS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth pieris.com|PIRS - Net earnings per share growth this year|Earnings growth forecast for next year Pieris Pharmaceuticals
- revenue and sales details:
PIRS - Company Total Revenue|Company Future Sales Volume Pieris Pharmaceuticals, Inc.|PIRS - P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharma
Comprehensive company analysis:Pieris Pharmaceuticals, Inc. (PIRS)
Product sample of Pieris Pharmaceuticals

The forward P/S ratio compares current market capitalization with projected sales volume, allowing for an assessment of market expectations regarding revenue growth rates prior to the release of official financial reports. An analysis of the forward P/S history reveals the operational resilience of Pieris Pharmaceuticals (PIRS), demonstrating how investors value the commercialization potential of Anticalin proteins within the context of an academic approach to drug development.

Key competitors

Price-to-Projected Revenue Ratio Haleon HLN|KVUE (Kenvue Inc) - Future Price to Revenue|Verona Pharma Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Jyong Bio MENS|LGND: Forward P/S Multiple|Market Cap to Future Revenue Ratio amneal.com (AMRX)|Price-to-Projected Revenue Ratio Perrigo|ALVO: Forward Price to Sales|Forward P/S Multiple LQDA|Market Cap to Expected Sales Ratio Galapagos Corp|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|Market Cap to Expected Sales Ratio mannkindcorp.com (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira Pharmaceuticals)|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|Future Price to Revenue TBPH (Theravance Corp)|AQST (Aquestive Therapeutics) - Forward P/S Multiple|SCPH: Forward Price to Sales|Forward P/S Multiple TECX|Forward P/S Multiple Tonix Pharma (TNXP)|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|invizyne.com (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|Entera Bio (ENTX) - Forward P/S Multiple|HYFT (MindWalk) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ABVC BioPharma, Inc (ABVC)|Forward P/S Multiple CPIX|QNTM - Market Cap to Future Revenue Ratio|FibroGen - Forward Price-to-Revenue Multiple|Forward P/S Multiple Telomir Pharmaceuticals Inc TELO|RANI: Forward Price-to-Revenue Multiple|Synergy CHC Corp - Price to Expected Revenue Ratio|RLYB: Forward P/S Multiple|LEXX - Market Cap to Expected Sales Ratio|PULM (Pulmatrix) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Pheton (PTHL)|Forward P/S Multiple APM|Forward P/S Multiple Lyra Therapeutics Inc (LYRA)|Price-to-Projected Revenue Ratio Impact BioMedical Inc IBO|TNF Pharmaceuticals Inc. - Price-to-Projected Revenue Ratio|YCBD - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio PainReform Ltd PRFX|altamiratherapeutics.com (CYTO) - Price-to-Projected Revenue Ratio|Future Price to Revenue LIPO (Lipella Pharma)|OPTN (OptiNose, Inc.) - Forward P/S Multiple|procapsgroup.com (PROC) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|QLI (Qilian International Holding Group) - Forward Price to Sales|Price-to-Projected Revenue Ratio ACELYRIN, Inc. SLRN|Market Cap to Expected Sales Ratio TFF Pharmaceuticals, Inc (TFFP)